CHENGDU, China, Dec. 23, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, has been invited to present at the Second Annual China Forum of the Fifth Annual OneMedForum San Francisco 2012 on January 9, 2012, at Sir Francis Drake Hotel at 450 Powell Street, San Francisco, CA 94102. About OneMedForum The OneMedForum San Francisco conference, launched in 2008, runs concurrently with J.P Morgan conference that provides an efficient access to the companies that shape the future of the rapidly changing healthcare landscape with company presentations, panels and workshops for strategic insights and practical benefits. The 2nd Annual China Forum will take place on Monday, January 9, 2012 at 1:00-4:00 pm at the Sir Francis Drake Hotel in San Francisco, as part of the 5th Annual OneMedForum SF 2012 on January 9-12, 2012. China Forum II: Pursuing the Healthcare Market in China is designed to help senior executives shape strategy to approach what is one of the most lucrative and perilous markets in the world. The program will consist of four panel sessions that will address critical issues to understanding how Healthcare and life science companies can succeed in China. Attendees will include institutional investors, senior healthcare executives and life science executives looking for investment opportunities, market insights, licensing opportunities, acquisitions, joint ventures and strategic partnerships. Additional information regarding the China forum can be found on: www.onemedplace.com/forum/presentation/china-panelsAbout TPI Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees. For more information about TPI, please visit: http://www.tianyinpharma.comSafe Harbor Statement The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.